medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Blood glucose is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19 in Wuhan, China

Jin-Kui Yang MD, PhD[1]✉#, Jian-Min Jin MD, PhD[2,3] ✉#, Shi Liu, MD[3]✉, Peng Bai, MD[2,3], Wei He, MD[4,3], Fei Wu, MD[3], Xiao-Fang Liu, MD, PhD[2], De-Min Han MD, PhD[5]

[1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. ✉Electronic address: jkyang@ccmu.edu.cn

[2]Department of Respiratory and Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. ✉Electronic address: jinjianmin1972@sina.com

[3]Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

[4]Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. ✉Electronic address:1455019296@qq.com

[5]Department of otolaryngology and head surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

# These authors contributed equally to this paper.

✉Address correspondence and reprint requests to

Professor Jin-Kui YANG, Department of Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Tel: +86-10-58268445

Fax: +86-10-65288736

Cell: +86-13911167636

jkyang@ccmu.edu.cn

or

Dr. Jian-Min Jin, Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Jian-Min Jin: jinjianmin1972@sina.com

or

Professor Shi Liu, Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

E-mail: 1455019296@qq.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

OBJECTIVE Most patients with Coronavirus Disease 2019 (COVID-19) were *Mild* or *Moderate*. *Severe* patients progressed rapidly to *Critical* condition including multi-organ failure and even death. Identification of early predictive factors is urgently necessary to facilitate appropriate intensive care.

METHODS We included all patient admitted to Wuhan Union Hospital and treated by the supportive medical team of Beijing Tongren Hospital as of March 20, 2020. Indicators of injuries for multiple organs, including the heart, kidney and liver, and glucose homeostasis were specifically analyzed for predicting primary outcomes (an intensive care unit (ICU) or death).

RESULTS The data of 120 patients with a severity equal to or greater than *Moderate*, discharged or died were extracted. After excluding patients with history of diabetes, chronic heart, kidney, and liver disease, 69 patients were included in the final analysis. There were 26 cases with primary outcomes including 16 deaths. Univariable analysis indicated that fasting blood glucose (FBG), lactate dehydrogenase (LDH), hydroxybutyrate dehydrogenase (HBDH), creatine kinase and creatinine were associated with primary outcomes and death. Among patients with primary outcomes, although FBG levels were much higher on admission, they dramatically decreased subsequently, while in deceased patients they increased continuously. Multivariable Cox regression indicated that FBG≥7mmol/L was the only independent predictor for death (HR = 3.75, 95% CI 1.26-11.15). Cluster analysis found more proximities of FBG (at the time of admission) with LDH, HDDH or Creatinine (after 2-4 days of hospitalization) (r=0.43, 0.43 and 0.50, respectively, P<0.01 for all).

Conclusions Blood glucose is a representative of the clustered indicators of multi-organ injury and earlier predictor for poor outcomes and death in the COVID patients. As it is easy to perform for clinical practices and self-monitoring, glucose testing will be much helpful for predicting poor outcomes to facilitate appropriate intensive care.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

In early December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) pneumonia disease (COVID-19) occurred in Wuhan, China (1). Most patients with COVID-19 were *Mild*. *Moderate* patients often experienced dyspnea after one week. *Severe* patients progressed rapidly to critical condition including multi-organ failure and even death. Identification of early predictive factors for poor outcomes is urgently necessary to facilitate appropriate intensive care.

Although many case series studies have been published, the final clinical outcomes in most of these series remained unknown at the time of publication. Most importantly, clinical biochemical testing items were not uniform and without regular longitudinal testing. Some of the most accessible biochemical parameters, such as blood glucose were not assessed (2-5). Therefore, the estimation of risk factors for the severity and mortality of COVID-19 is not very robust.

We have previously reported that hyperglycemia was commonly present in SARS patients without prior history of diabetes and without using glucocorticoids, and was an independent predictor for mortality in SARS patients (6). Binding of SARS coronavirus to the ACE2 receptor may damage islets and causes acute diabetes (7), as seen with *ACE2* gene knockout leading to diabetes in mice (8).

SARS-CoV-2 infection is reminiscent of the SARS-CoV outbreak in early 2003, because both viruses attack cells via the same ACE2 receptor (9). In this observational cohort study, we aim to explore whether some organ damage including insulin-secreting pancreatic islet was already occurred at an early stage and hereby increased the risk of mortality later.

Methods

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Participants

This retrospective cohort study included consecutive COVID-19 adult inpatients (≥18 years old) admitted to Wuhan Union Hospital (Wuhan, China) and treated by the supportive medical team of Beijing Tongren Hospital (Beijing, China) from January 29, 2020, to March 20, 2020. Wuhan Union Hospital was assigned responsibility for the treatments of severe COVID-19 patients by the Wuhan government. Therefore, there are no mild COVID-19 patient and a uniformed protocol of clinical practices was used in this cohort.

Respiratory specimens were collected by the local center for disease control and prevention (CDC) and then shipped to designated authoritative laboratories to detect SARS-CoV-2. The presence of SARS-CoV-2 in respiratory specimens was detected by real-time RT-PCR methods. The RT-PCR assay was conducted as per the protocol established by the World Health Organization (WHO).

For the identification of indicators of early multi-organ injury for predicting poor outcomes, patients with a history of chronic organ damage, including heart disease(myocardial infarction and heart failure), kidney disease (maintenance dialysis or renal transplantation), liver disease (liver cirrhosis) or insulin-secreting pancreatic islet disease (diabetes) were excluded. Patients who received glucocorticoid treatment were also excluded to avoid glucocorticoid-induced diabetes. The clinical outcomes including an intensive care unit (ICU) or in-hospital death were monitored up to March 24, 2020, the final date of follow-up.

The Research Ethics Commission of Beijing Tongren Hospital, Capital Medical University (TRECKY2020-013) approved the study and the Ethics Commission waived the requirement for informed consent.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Data collection

Demographic, clinical, laboratory and outcome data were extracted from the electronic hospital information system using a standardized form. All medical data were checked by two medical doctors (JMJ and PB) and the leader author (JKY) adjudicated any different interpretation between the two medical doctors.

Definitions

Diagnosis and clinical classification criteria and treatment plan (version 6.0) of COVID-19 was launched by the National Health Committee of China (http://www.nhc.gov.cn/). The clinical classification of severity is as follows: (1) *Mild*, having only mild symptoms, imaging shows no pneumonia. (2) *Moderate*, with fever, respiratory tract symptoms, and imaging shows pneumonia. (3) *Severe*, meet any of the following signs: a) respiratory distress, respiratory rate ≥ 30 beats / min; b) in the resting state, finger oxygen saturation ≤ 93%) arterial blood oxygen partial pressure (PaO_2/oxygen concentration (FiO_2) ≤ 300mmHg (1mmHg = 0.133kPa). (4) *Critical*, one of the following conditions: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.

Immunohistochemical patterns of ACE2

Lung, pancreas, heart, kidney and liver tissue was obtained from a 43-year-old brain-dead organ donor after informed consent from his wife. The protocol was approved by the ethics committee of Beijing Tongren Hospital, Capital Medical University. Serial sections were made from each of the tissues, and ACE2 immunohistochemical staining was compared with negative controls. A qualified pathologist interrelated the results of ACE2 expression.

Statistical analysis

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Data were expressed as median (interquartile range (IQR)) or percentage, as appropriate. Comparison of continuous data among different severity groups and between the deceased and survivor groups were determined using a Kruskal-Wallis test and Mann-Whitney U test, respectively. Chi-square (χ^2) test for trend and two-group Chi-square tests or Fisher's exact tests were used for categorical variables as appropriate. Proximity Matrix and Dendrogram of six measures as different organ damage indicators were calculated and developed by Hierarchical cluster analysis. To explore the risk factors associated with poor outcomes, univariate and multivariate logistic regression models were used. To find the risk factors predicting in-hospital death, univariate and multivariate Cox proportional hazard model were used to calculated hazard ratio (HR). Considering the relatively small number of poor outcomes and deaths in this study and to avoid overfitting in the model, age, gender, and five variables indicating different organs damage were chosen for multivariable analysis. Kaplan–Meier survival curves and the log-rank test were used for testing the survival between normal and abnormal indicators. SPSS for Windows 17.0 and Graphpad prism 7.0 software were used for statistical analysis, with statistical significance set at 2-sided $P<0.05$.

Results

Demographic and clinical characteristics

A total of 120 consecutive COVID-19 adult inpatients (≥18 years old) were admitted to Wuhan Union Hospital (Wuhan, China) and treated by the supportive medical team of Beijing Tongren Hospital (Beijing, China) from January 29, 2020 to March 20, 2020. Because Wuhan Union Hospital was assigned responsibility for the treatments of severe COVID-19 patients by the Wuhan government, most patients were *Severe* or

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Critical, some were *Moderate*, but none were *Mild* according to the guidance provided by the Chinese National Health Commission. Exclusion criteria included: still hospitalized patients as of March 24, 2020, patients with chronic organ damage (history of myocardial infarction, heart failure, dialysis, renal transplant, cirrhosis, diabetes), and patients missing basic medical information. Ultimately, 69 patients were included in the final analysis.

Of the 69 patients, 23 were *Moderate*, 20 were *Severe*, and 26 were *Critical* based on severity classification. There were 53 survivors and 16 deceased patients in this study (Table 1). Of the deceased patients, the median (interquartile ranges, IQR) period from symptom onset to death and the median (IQR) period from hospitalization to death were 14 (10-22) days and 3 (3-7) days, respectively.

In this hospital-based cohort, the median age of the 69 patients was 61 years (IQR, 52 to 67). Older patients tend to be more serious (χ^2 test for trend, p=0.024), but no significant difference of age was present between survivors and deceased patients within hospitalized patients.

The ratio of male to female patients were relatively similar, with 49.3% males. However, the proportion of males in survivors and deceased patients were 39.6% and 81.2%, respectively, suggestive that males may have higher mortality from COVID-19 (relative risk (95% CI): 2.0 (1.28-3.02), χ^2 test, P=0.004).

Fever (89.9), cough (65.2%) and dyspnea (43.5%) were the most common symptoms, while sputum (17.4%) and diarrhea (17.4%) were less common.

An increase in white blood cells and neutrophils, and decrease in lymphocytes and platelets occurred in both *Critical* and deceased patients at the time of admissiom. And these changes became more obvious at the time after 2-4 days of hospitalization.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

A slight transient decrease in blood potassium and sodium ion levels was seen in *Critical* patients. A persistent decrease of albumin and increase of globulin were present in *Critical* and deceased patients (Table 1).

C-reactive protein was increased at the time of admission but dramatically and significantly decreased to the normal range at the time after 2-4 days of hospitalization in survivors. A persistent increase of C-reactive protein was present in deceased patients (Table 1).

Indicators of multi-organ injury

To investigate multi-organ injury caused by the virus, the ACE2 protein expression profile was analyzed in tissues, including the lung, heart, liver, kidney, and pancreas which was obtained from the organ donor. In the lung, ACE2 immunostaining was abundant in epithelial cells of bronchioles and pulmonary alveoli. In the heart, it was highly expressed in the myocardium. According to our previous study in the mouse pancreas, ACE2 was strongly expressed in pancreatic endocrine islet(8). Indeed, compared to the negative controls, ACE2 was intensely stained in the pancreatic endocrine islets, but very weakly stained in pancreatic exocrine tissues. In the kidney, ACE2 was strong in glomerular parietal epithelial cells and weak in the visceral epithelial cells. Interestingly, ACE2 expression was negative in the liver. Moreover, ACE2 was also negative in the endothelial lining of the hepatic sinusoids (Figure 1A).

Fasting blood glucose (FBG), lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and creatinine (Cr) were used as indicators for the relative function of multiple organs (i.e., insulin-secreting pancreatic islet, heart, liver, and kidney injury, respectively). In parallel with the expression profiles of ACE2 in different organs, indicators of the relative function of multiple organs except the liver

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

can predict death. Kaplan-Meier analysis revealed a significantly higher in-hospital death rate for patients with elevated indicators for relative multi-organ injury, i.e., FBG ≥ 7.0mmol/L for the pancreatic islet, LDH ≥ 250 IU/L for the heart, Cr ≥ 97 μmol/L for the kidney and ALT ≥ 40 IU/L for the liver (Figure 1B).

Indicators including creatine kinase (CK), MB isoenzyme of creatine kinase (CK-MB), aspartate aminotransferase (AST), hydroxybutyrate dehydrogenase (HBDH), alkline phosphatase (AKP), and blood urea nitrogen (BUN) were also tested at the time of admission and during subsequent treatment. Indicators of cardiac injury, including LDH, HBDH, CK, and CK-MB, were remarkably increased in *Critical* and deceased patients. Kidney injury, indicated by BUN and Cr elevations, was observed in deceased patients. Liver injury, indicated by ALT and AST levels, was not observed at the time of admission and at the time after 2-4 days of hospitalization. (Table 1).

Longitudinal changes of the indicators

FBG and LDH levels were much higher above the upper limit of normal value at the time of admission and at the time after 2-4 days of hospitalization in the *Critical* group, while FBG and LDH levels did not increase remarkably in *Severe* and *Moderate* groups. However, Cr and ALT levels were not remarkably different among *Moderate*, *Severe* and *Critical* groups (Figure 1C). To further find the predictive values of these four indicators, a longitudinal case-control investigation was conducted in *Critical* patients, considering that the in-hospital deaths happened only in *Critical* patients in this cohort. The patients with test values for at least three time points were selected in *Critical* patients. Because the median (IQR) period from hospitalization to death was 3 (3-7) days and the clinical parameters were tested every 2-4 days, only 5 *Critical* patients who survived and 5 *Critical* patients who died were

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

compared. It is meaningful to find out that although FBG and LDH levels were much higher above the upper limit of normal value at the time of admission, they dramatically decreased to the normal range during subsequent treatment in *Critical* patients who survived. However, of the patients who died, increases of FBG and LDH levels continued (Figure 1D-E). These changing trends of Cr and ALT levels in survived and deceased patients were not found (Figure 1F-G).

The independent indicators for poor outcomes

In univariable Logistic regression analysis, odds of critical condition were higher in patients with old age, elevated FBG, LDH, and HBDH (Figure 2A). In the multivariable analysis, FBG (OR:6.54, 95%CI: 1.18-36.08) and HBDH (OR:6.54, 95%CI: 1.18-36.08) were independent risk factor of critical condition (Figure 2B).

Using the univariable Cox proportional hazards model, male sex (HR = 5.02, 95% CI 1.43-17.62), elevated FBG (HR = 5.09, 95% CI 1.76-14.70), LDH (HR = 9.73, 95% CI 1.28-73.7) and HBDH (HR = 3.81, 95% CI 1.23-11.85) were predictors for death (Figure 2C). In the multivariable model, elevated FBG remained the only independent predictor for death (HR = 3.75, 95% CI 1.26-11.15) (Figure 2D).

To interpret the difference of univariable and multivariable regression results which suggested that these indicators were interdependent to each other, Hierarchical cluster analysis of six indicators was performed. At the time of admission (a), significant proximities of LDH (a) with HBDH (a) (r=0.73, P<0.01) and CK (a) with HBDH (a) (r=0.49, P<0.01) were present. No significant proximities of FBG (a) with other Variables (a), ALT(a) with other Variables (a) and Cr (a) with other Variables were observed. These results suggested that some definite indicators for multi-organ failure were independent. However, at the time after 2-4 days of hospitalization (b), more

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

significant proximities among Variables (b), especially FBG (b) with other Variables (b) were found. These suggested that multi-organ injury might present at the same time caused by the virus infection. Most interestingly, significant proximities of FBG (a) (at the time of admission) with other Variables (b) (at the time after 2-4 days of hospitalization) including LDH (b) (r=0.43, P<0.01), HDDH (b) (r=0.43, P<0.01), Cr (b) (r=0.50, P<0.01) were present. Therefore, abnormal glucose homeostasis indicated the relative dysfunction of pancreatic islet occurred earlier than that of other organs (Table 2). The dendrogram of Variables (b) (at the time after 2-4 days of hospitalization) suggested more proximity of FBG with LDH/HBDH equations than the other equations. Heart injury indicated by LDH/HBDH and relative islet dysfunction indicated by FBG was in a cluster solution if setting distance at 15 according to the Hierarchical cluster analysis (Figure 2E). This suggests that FBG and LDH/HBDH are interdependent to each other. Furthermore, results of the cluster analysis can interpret why the multivariable regression results indicated that FBG is the only independent predictor for in-hospital death.

Conclusions

In this study, for the first time, we identified early indicators of multi-organ injury for predicting severity and mortality in patients with COVID-19. Elevation of FBG, LDH, HBDH, CK and Cr were associated with higher odds of critical condition and a higher hazards ratio of in-hospital death. In particular, Hierarchical cluster analysis suggested that some definite indicators for multi-organ failure were interdependent to each other, indicating that multi-organ injury was present at the same time caused by the virus infection. Multivariable regression results indicated that FBG is the only independent predictor for in-hospital death.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The multi-organ nature of COVID-19 or SARS-CoV-2 infection has been demonstrated in a latest autopsy studies (10). Moreover, an autopsy study on 3 cases of SARS indicate that some lesions observed in heart, kidney, pancreas may have existed before the hospitalization (11). We found that the SARS-CoV-2 receptor, ACE2 is highly expressed in multiple organs including the lung, the heart, the kidney and the pancreatic islet.

Acute heart injury (AHI) such as acute myocarditis is common in patients with viral infection, such as adenovirus, herpesvirus and enterovirus (12). Since carditis associated with coronavirus infection was first reported in 1980 (13), growing evidence shows that coronavirus is also a pathogen for AHI that should not be ignored. Early in 2003,we reported that SARS-CoV may cause AHI and elevated LDH is an independent predictor for in-hospital death in SARS patients (7). A report from Saudi Arabia indicated that Middle East Respiratory Syndrome coronavirus (MERS-CoV) could cause acute myocarditis and acute-onset heart failure (14). The latest case report described cardiac involvement in a patient with COVID-19 (15). Two myocardial enzymes, LDH and HBDH exist in myocardia and release into blood flow once the myocardial injury happens. In this study, we found that both high LDH and HBDH on admission were predictor for severity and in-hospital death.

Acute kidney injury (AKI), same as AHI, is also common in patients with virus infection, such as Parvovirus B19, Hanta, Ebola, and Dengue virus infection (16). Coronavirus associated AKI was reported in patients with MDRS (17). In the previous report, we found that SARS-CoV may cause AKI and elevated Cr is an independent predictor for in-hospital death in SARS patients (7). In this study, we found that elevation of both BUN and Cr were present in *Critical* and deceased patients. High Cr

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

on admission were predictor for severity and in-hospital death in COVID-19 patients.

Acute liver injury (ALI) was reported in SARS patients, which was manifested with mild elevation of ALT/AST levels. Decreased serum albumin levels was present in some patients. However, ALT and AST was not an independent predictor of poor outcome (18). A number of studies have shown that elevated liver enzymes and decreased albumin levels were present in patients with MERS (19). Case reports suggested that patients with severe COVID-19 seem to have higher rates of liver dysfunction (20). However, few studies have shown the liver enzymes were independent predictor for poor outcome and mortality in COVID-19 patients. In this study, although mild decrease of albumin was found in *Critical* and deceased patients, significant differences of liver enzymes were not found between survivors and deceased patients in this cohort. We propose that liver injury may not be a direct damage caused by the virus, because we found that expression of the SARS-CoV-2 receptor, ACE2 in the liver is very low.

Acute pancreatic islet injury (AIsI) caused by virus infection has scarcely been reported. Subacute islet injury caused by virus infection has been widely reported in type 1 diabetes, which is an autoimmune disease characterized by a long-term loss of pancreatic islet β-cells. However, serological evidence of infection and isolation of viruses from the pancreas have been reported in a few cases of recently diagnosed acute diabetes (21). A case-control study indicated that high FBG is an independent predictor for severity of H1N1 pneumonia. In this study, FBG was remarkably increased in patients with H1N1 pneumonia than in patients with non-H1N1 pneumonia (8.3 vs. 6.2 mmol/L). Moreover, compensative rise in insulin, in corresponding with high FBG was not found; instated, islet β-cells function indicated

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

by HOMA-β index is relatively lower (103 vs. 134) (22).

It is reasonable to think that FBG elevation maybe caused by "Stress hyperglycemia" during acute illness in patients with COVID-19. However, severe hyperglycemia is related to both insulin secretion and insulin resistance. Insulin resistance caused by metabolic, hormonal, and cytokine changes associated with the illness demands a corresponding rise in insulin output in order to maintain normal glycemia. Only when the compensation is lost will blood glucose increase significantly (23, 24). Therefore, relative dysfunction of pancreatic islet insulin secretion caused by the virus infection maybe the main reason of severe hyperglycemia in patients with COVID.

Additionally, consistent with many previous reports, male gender, changes of blood cell counting, persistent increase of C-reactive protein on admission and during subsequent treatment were associated with higher poor outcomes in this study.

There are several limitations in our study. First, due to the critical condition of the disease, laboratory examinations were performed according to the clinical care needs of the patient, longitudinal testing interval was not firm and were performed every 2-4 days. Laboratory data at some points is missing. Second, we only assessed multi-organ injury from the perspective of some most accessible biochemical parameters. It would would have produced better results if some more specific indicators such as echocardiography, glomerular filtration rate and serum insulin levels were also measured in this study, and if we could assess some organ injury-specific mortality. Last but not least, interpretation might be limited by the sample size of the study. However, by including all patients of department of critical care medicine in the designated hospitals, we believe our study population of

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 is a representative of patients treated in Wuhan.

In summary, except pneumonia, multi-organ injury including the heart, kidney, and possibly pancreatic islet injuries was already occurred at an early stage and thereby increased the risk of mortality later in patients with COVID-19. These multi-organ injury indicators including LDH, HBDH, CK, Cr and FBG were associated with higher odds of primary outcomes and death. However, these indicators are clustered interdependent to each other, indicating that the multi-organ damage happened at the same time as the infection. Among them, FBG is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19. As it is easy to perform for clinical practices and self-monitoring, FBG testing will be much helpful for predicting critical condition to facilitate appropriate intensive care.

Article Information

Funding. This study was funded by the National Key R&D Program of China (2017YFC0909600).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. J.K.Y. designed and performed the analysis and wrote the manuscript. J.M.J., P.B., F.G., W.H., F.W., and S.L. collected the epidemiological and clinical data and processed statistical data. J.K.Y., J.M.J. and D.M.H. revised the final manuscript. J.K.Y., J.M.J. and S.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.

3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507-13.

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020.

5. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ*. 2020;368:m606.

6. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. *Diabet Med.* 2006;23(6):623-8.

7. Yang JK, Lin SS, Ji XJ, and Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetol.* 2010;47(3):193-9.

8. Niu MJ, Yang JK, Lin SS, Ji XJ, and Guo LM. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. *Endocrine*. 2008;34(1-3):56-61.

9. National Health Commission of PRC: Feb 23: Daily briefing on novel coronavirus cases in China. *http://ennhcgovcn/2020-02/23/c_76779htm*.

10. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. *Zhonghua Bing Li Xue Za Zhi*. 2020;49(0):E009.

11. Lang Z, Zhang L, Zhang S, Meng X, Li J, Song C, et al. Pathological study on severe acute respiratory syndrome. *Chin Med J (Engl).* 2003;116(7):976-80.

12. Pollack A, Kontorovich AR, Fuster V, and Dec GW. Viral myocarditis--diagnosis, treatment options, and current controversies. *Nat Rev Cardiol*. 2015;12(11):670-80.

13. Riski H, Hovi T, and Frick MH. Carditis associated with coronavirus infection. *Lancet.* 1980;2(8185):100-1.

14. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. *Ann Saudi Med.* 2016;36(1):78-80.

15. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020.

16. Prasad N, Novak JE, and Patel MR. Kidney Diseases Associated With Parvovirus B19, Hanta, Ebola, and Dengue Virus Infection: A Brief Review. *Adv Chronic Kidney Dis.* 2019;26(3):207-19.

17. Mackay IM, and Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. *Virol J.* 2015;12:222.

18. Wu KL, Lu SN, Changchien CS, Chiu KW, Kuo CH, Chuah SK, et al. Sequential changes of serum aminotransferase levels in patients with severe acute respiratory syndrome. *Am J Trop Med Hyg*. 2004;71(2):125-8.

19. Xu L, Liu J, Lu M, Yang D, and Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int.* 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

20. Cui Y, Tian M, Huang D, Wang X, Huang Y, Fan L, et al. A 55-Day-Old Female Infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. *J Infect Dis.* 2020.

21. Jaeckel E, Manns M, and Von Herrath M. Viruses and diabetes. *Ann N Y Acad Sci*. 2002;958:7-25.

22. Wang W, Chen H, Li Q, Qiu B, Wang J, Sun X, et al. Fasting plasma glucose is an independent predictor for severity of H1N1 pneumonia. *BMC Infect Dis.* 2011;11:104.

23. Gupta D, Krueger CB, and Lastra G. Over-nutrition, obesity and insulin resistance in the development of beta-cell dysfunction. *Curr Diabetes Rev.* 2012;8(2):76-83.

24. Dungan KM, Braithwaite SS, and Preiser JC. Stress hyperglycaemia. *Lancet*. 2009;373(9677):1798-807.

Table 1: Demography, clinical and laboratory parameters of patients with COVID-19

		All patients (n=69)	Severity				Mortality		
			Moderate (n=23)	Severe (n=20)	Critical (n=26)	P value	Survivor (n=53)	Deceased (n=16)	P value
Age—yrs		61 (52-67)	56 (47-64)	62 (55-67)	65 (57-71)	**0.024**‡	60 (51-67)	64 (57-68)	0.232†
Male sex—n (%)		34 (49.3)	9 (39.1)	8 (40.0)	16 (61.5)	0.111#	21(39.6)	13 (81.2)	**0.003**!
Symptoms									
Fever—n (%)		62 (89.9)	18 (78.3)	19 (95.0)	25 (96.2)	**0.041**#	47 (88.7)	15 (93.8)	0.340!
Cough—n (%)		45 (65.2)	13 (56.5)	13 (65.0)	19 (73.1)	0.225#	32 (60.4)	13 (81.3)	0.077!
Sputum—n (%)		12 (17.4)	5 (21.7)	4 (20.0)	3 (11.5)	0.341#	10 (18.9)	2 (12.5)	0.265!
Dyspnea—n (%)		30 (43.5)	7 (30.4)	7 (35.0)	16 (61.5)	**0.026**#	22 (41.5)	8 (50.0)	0.188!
Fatigue—n (%)		26 (37.7)	8 (34.8)	6 (30.0)	12 (46.2)	0.397#	18 (34.0)	8 (50.0)	0.118!
Diarrhea—n (%)		12 (17.4)	2 (8.7)	5 (25.0)	5 (19.2)	0.350#	9 (17.0)	3 (18.8)	0.282!
From onset to hospitalization—days		12.0 (9.0-14.0)	13.0 (10.0,15.0)	11.5 (7.8,14.0)	12.0 (7.0,14.0)	0.273‡	13.0 (10.0,14.0)	11.5 (7.3,14.0)	0.348†
Haemoglobin—g/L	**(a)**	127 (116-139)	124 (117-137)	119 (110-143)	130 (121-147)	.477‡	125 (115-136)	131 (122-151)	.233†
	(b)	126 (116-140)	130 (113-141)	123 (115-134)	128 (118-143)	.704‡	124 (116-137)	137 (118-149)	.200†
Platelet count—$\times 10^9$/L	**(a)**	211(183-282)	215 (192-286)	215 (196-293)	205 (159-263)	.515‡	219 (193-290)	197 (146-234)	.067†
	(b)	232 (171-359)	258 (184-367)	316 (186-443)	189 (135-257)	.061‡	258 (185-385)	151 (132-190)	**.002**†
White blood cell count—$\times 10^9$/L	**(a)**	6.2 (4.7-8.2)	5.7 (4.3-7.4)	5. 9 (4.8-8.1)	7.7 (5.9-9.7)	**.009**‡	5.9 (4.6-7.6)	8.1 (6.3-9.5)	**.002**†
	(b)	6.9 (4.8-9.0)	5.9 (4.7-8.7)	6.2 (4.1-8.5)	8.0 (5.9-10.4)	.076‡	6.0 (4.7-8.7)	8.7 (7.1-12.4)	**.007**†
Neutrophil count—$\times 10^9$/L	**(a)**	4.5 (3.1-6.7)	3.3 (2.7-4.9)	4.2 (3.7-5.9)	6.7 (5.4-8.8)	**.000**‡	4.0 (3.0-5.9)	7.0 (5.6-8.4)	**.000**†
	(b)	4.9 (3.4-7.6)	3.6 (2.9-5.8)	4.1 (2.7-6.0)	6.7 (4.9-8.5)	**.005**‡	4.2 (3.2-6.2)	7.8 (6.1-11.5)	**.000**†
Lymphocyte count—$\times 10^9$/L	**(a)**	1.0 (0.7-1.4)	1.3 (0.9-1.7)	0.9 (0.7-1.4)	0.7 (0.4-1.1)	**.000**‡	1.0 (0.7-1.5)	0.6 (0.4-1.1)	**.002**†
	(b)	1.1 (0.7-1.4)	1.3 (1.1-1.9)	1.1 (1.0-1.6)	0.7 (0.5-1.0)	**.003**‡	1.2 (1.0-1.6)	0.6 (0.3-0.7)	**.000**†
Potassium—mmol/L	**(a)**	3.9 (3.5-4.3)	4.1 (3.9-4.4)	3.8 (3.5-4.5)	3.7 (3.2-4.0)	**.025**‡	3.9 (3.5-4.3)	3.9 (3.6-4.3)	.789†
	(b)	4.2 (3.8-4.5)	4.4 (4.2-4.8)	4.1 (3.8-4.5)	3.8 (3.7-4.3)	.084‡	4.2 (3.8-4.5)	4.0 (3.7-4.6)	.659†
Sodium—mmol/L	**(a)**	139 (137-142)	140 (138-142)	141 (138-143)	138 (135-141)	.078‡	140 (138-142)	137 (135-141)	**.008**†
	(b)	139 (137-143)	140 (137-142)	141 (138-143)	138 (136-142)	.517‡	139 (138-142)	138 (135-143)	.335†
Chloride—mmol/L	**(a)**	104 (99-106)	105 (102-106)	104 (100-108)	103 (98-105)	.109‡	104 (100-106)	103 (98-106)	.136†

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

	(b)	103 (101-106)	102 (102-104)	104 (101-109)	103 (101-104)	.757‡	103 (101-107)	103 (101-104)	.701†
Albumin—g/L	**(a)**	29 (27-34)	34 (30-39)	28 (26-31)	28 (25-30)	**.001**‡	30 (27-35)	28 (25-29)	.091†
	(b)	29 (26-33)	33 (29-40)	30 (28-33)	26 (23-29)	**.000**‡	30 (27-33)	26 (22-28)	**.001**†
Globulin—g/L	**(a)**	32 (29-36)	30 (26-34)	32 (30-38)	34 (30-39)	**.027**‡	31 (29-35)	36 (31-39)	.038†
	(b)	33 (30-37)	30 (27-34)	32 (28-37)	35 (32-39)	**.008**‡	32 (29-36)	35 (32-38)	.079†
C-reactive protein—mg/L	**(a)**	36 (5-77)] **	4 (1-36)	23 (7-65)	60 (47-100)	**.000**‡	31 (3-60)] **	80 (41-119)	**.001**†
	(b)	**8 (3-51)**	4 (2-7)	6 (3-10)	67 (28-104)	**.000**‡	**6 (2-14)**	78 (51-105)	**.000**†
Alanine aminotransferase—U/L	**(a)**	38 (24-52)	39 (21-49)	37 (24-55)	36 (27-52)	.641‡	37 (24-52)	38 (24-51)	.806†
	(b)	30 (22-62)	32 (21-68)	31 (21-72)	38 (26-56)	.641‡	35 (22-69)	38 (26-56)	.912†
Aspartate aminotransferase—U/L	**(a)**	33 (23-47)	23 (17-34)	35 (28-50)	35 (29-56)	**.007**‡	32 (20-47)	36 (29-83)	.067†
	(b)	27 (21-46)	22 (18-30)	34 (22-45)	28 (22-54)	.108‡	25 (21-41)	34 (23-57)	.166†
Alkaline phosphatase—U/L	**(a)**	57 (48-67)	55 (46-70)	55 (41-62)	61 (53-79)	.067‡	57 (47-66)	60 (50-88)	.224†
	(b)	65 (54-80)	62 (51-72)	59 (50-80)	71 (58-133)	.105‡	61 (52-76)	74 (55-162)	.075†
Lactate dehydrogenase—U/L	**(a)**	312 (204-483)	196 (137-251)	294 (242-384)	499 (354-587)	**.000**‡	260 (192-379)	544 (476-608)	**.000**†
	(b)	267 (219-419)	207 (146-240)	246 (212-305)	425 (275-616)	**.000**‡	242 (206-283)	593 (425-875)	**.000**†
Hydroxybutyrate dehydrogenase—U/L	**(a)**	253 (190-368)	161 (118-218)	252 (192-329)	387 (313-478)	**.000**‡	227 (172-316)	343 (334-526)	**.000**†
	(b)	209 (147-282)	154 (132-192)	185 (148-220)	435 (243-687)	**.000**‡	186 (146-230)	474 (329-858)	**.000**†
Creatine kinase—U/L	**(a)**	61 (47-143)	48 (36-66)	65 (41-122)	107 (54-275)	**.007**‡	56 (41-117)	116 (67-277)	**.009**†
	(b)	47 (33-66)	47 (33-57)	35 (23-49)	55 (37-100)	**.026**‡	42 (28-57)	67 (49-133)	**.003**†
Creatine kinase–MB—U/L	**(a)**	12 (9-19)	9 (7-12)	13 (9-21)	14 (10-23)	**.006**‡	11 (8-16)	17 (10-24)	**.045**†
	(b)	10 (7-16)	8 (7-10)	9 (7-15)	12 (9-22)	**.035**‡	8 (7-13)	19 (11-24)	**.008**†
Blood urea nitrogen—mmol/L	**(a)**	5.0 (3.4-6.7)	4.2 (3.3-5.5)	4.5 (2.9-6.9)	5.4 (4.0-7.7)	.158‡	4.4 (3.3-6.0)	6.4 (4.3-9.1)	**.004**†
	(b)	5.0 (3.9-6.7)	4.4 (4.1-5.9)	4.4 (3.3-5.6)	5.8 (4.2-8.2)	**.041**‡	4.5 (3.5-5.4)	7.5 (5.3-10.1)	**.001**†
Creatinine—μmol/L	**(a)**	66 (53-84)	64 (52-70)	61 (51-92)	70 (58-93)	.121‡	62 (52-73)	90 (68-101)	**.000**†
	(b)	62 (53-81)	57 (51-69)	63 (53-82)	66 (54-86)	.572‡	59 (51-74)	79 (63-101)	**.012**†
Fasting Blood Glucose—mmol/L	**(a)**	6.5 (5.7-7.6)	5.7 (5.3-6.5)	6.3 (5.6-6.8)	7.5 (6.4-8.7)	**.000**‡	6.1 (5.4-7.0)	7.4 (6.6-9.9)	**.001**†
	(b)	6.1 (5.5-7.5)	5.8 (5.4-6.1)	5.6 (5.2-6.3)	6.9 (6.4-9.4)	**.001**‡	5.8 (5.3-6.6)	7.4 (6.6-10.7)	**.000**†

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Parameters tested **(a)** on admission and **(b)** after 2-4 days of hospitalization. Data are median (IQR) or n (%). P values were calculated by Kruskal-Wallis Test (‡), Mann-Whitney U test (†), χ^2 test (#), or Fisher's exact test(!), as appropriate for group comparison analyses. **: P<0.01, Kruskal-Wallis Test, admission vs. 2-4 days after hospitalization.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2: Proximity Matrix of six multi-organ injury indicators by Hierarchical cluster analysis

		FBG (a)	LDH (a)	Cr (a)	CK (a)	HDDH (a)	ALT (a)
FBG (a) with **Variables (a)**	**FBG (a)**	1					
	LDH (a)	0.153	1				
	Cr (a)	0.135	0.240	1			
	CK (a)	0.067	0.236	0.011	1		
	HDDH (a)	0.224	**0.734	0.190	**0.488	1	
	ALT (a)	0.074	0.269	-0.075	0.075	0.211	1
		FBG (b)	**LDH (b)**	**Cr (b)**	**CK (b)**	**HDDH (b)**	**ALT (b)**
FBG (b) with **Variables (b)**	**FBG (b)**	1					
	LDH (b)	****0.576**	1				
	Cr (b)	****0.383**	0.274	1			
	CK (b)	0.167	0.331	0.119	1		
	HDDH (b)	****0.622**	**0.883	0.140	**0.388	1	
	ALT (b)	0.075	**0.445	0.264	0.021	0.252	1
		FBG (a)	**LDH (b)**	**Cr (b)**	**CK (b)**	**HDDH (b)**	**ALT (b)**
FBG (a) with **Variables (b)**	**FBG (a)**	1					
	LDH (b)	****0.433**	1				
	Cr (b)	****0.498**	0.265	1			
	CK (b)	0.025	*0.328	0.113	1		
	HDDH (b)	****0.428**	**0.881	0.128	**0.385	1	
	ALT (b)	0.099	**0.441	0.258	0.017	0.246	1

Parameters tested **(a)** on admission and **(b)** after 2-4 days of hospitalization. ** p<0.01; * P<0.05. Hierarchical cluster analysis, Pearson correlation test (2-tailed).

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure legend

Figure 1. Profile of ACE2 multi-organ expression and corresponding multi-organ injury.

(A) Immunohistochemically pattern of ACE2 (SARS-CoV-2 receptor) protein expression in different organs. (1-2) Lung: high expression of ACE2 was found in (1) bronchiolar epithelial cells and (2) alveolar epithelial cells. (3-5) Pancreas: serial sections including (3) Hematoxylin-Eosin (HE) stain showing the exocrine tissue of pancreas around and a pancreatic islet in the middle, (4) negative immunostaining control showing no non-specific staining, (5) expression of ACE2 in pancreas as assessed by immunohistochemistry showing endocrine tissue is strongly positive compared with exocrine tissue. (6) Heart: ACE2 was present in the myocytes, myocardium, border zone, endothelium of small-to-large arteries as well as sporadically within the smooth muscle of these vessels. (7) Kidney: ACE2 was very weakly present in glomerular visceral and parietal epithelium, but strongly present in the brush border and cytoplasm of proximal tubular cells, and in the cytoplasm of distal tubules and collecting ducts. (8) Liver: hepatocytes and other cells including the endothelium of sinusoids were negative.

(B) Kaplan–Meier survival curves for in-hospital death rate of patients with COVID-19 subgroup by indicators of multi-organ injury including: FBG ≥ 7.0mmol/L for the pancreatic islet; LDH ≥ 250 IU/L for the heart; Cr ≥ 97 μmol/L for the kidney and ALT ≥ 40 IU/L for the liver. log-rank test.

(C) At the time of (a) admission and (b) after 2-4 days of hospitalization, levels of FBG, LDH, Cr and ALT among *Critical*, *Severe* and *Moderate* patients with COVID-19 (mean ± s.e.m., *Moderate*, n=23; *Severe*, n= 20; and *Critical*, n=26).

(D-G) Longitudinal observation during admission and subsequent treatment, levels of **(D)** FBG, **(E)** LDH, **(F)** Cr, and **(G)** ALT in five survived *Critical* patients (S1-S5) (Left) and in five deceased *Critical* patients (D1-D5) (Right).

medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Effects of indicators of multi-organ injury on the risk of poor outcomes and in-hospital death in patients with COVID-19.

(A) Univariable Logistic regression indicated odds ratios (OR) for effects of indicators of multi-organ injury on poor outcomes.

(B) Multivariable Logistic regression indicated OR for effects of independent indicators of multi-organ injury on poor outcomes.

(C) Univariable Cox regression indicated effects of indicators of multi-organ injury on predicting in-hospital death.

(D) Multivariable Cox regression indicated effects of independent indicators of multi-organ injury on predicting in-hospital death.

(E) Hierarchical cluster analysis of six indicators indicated these indicators were interdependent to each other.

Figure 1

A



medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

B



C



D



E



F



G



Figure 2

A



B



D



medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058040; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

C



E